Drug Trial Radar · NCT04512963
Phase I Study of Progerinin in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 24, 2020
Primary completion
Jul 27, 2021
Study completion Jul 27, 2021
Sponsor
- Lead sponsor
- PRG Science & Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Amarex Clinical Research
- First posted
- Aug 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers. This is a first-in-human study. The study aims to determine the safety and tolerability of Progerinin after single and multiple doses in healthy volunteers and to evaluate the pharmacokinetics (PK) of Progerinin after single and multiple dose administrations in healthy volunteers.
Conditions
- Hutchinson-Gilford Progeria Syndrome
- Werner Syndrome
Interventions
ProgerininDrug
100 mg/g nano-suspension for oral use
PlaceboDrug
A substance that has no therapeutic effect, used as a control in testing Progerinin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Day 1 through 7 days after the last study drug administration
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through 7 days after the last study drug administration
- Incidence of withdrawals due to Adverse Events (AEs)Time frame: Day 1 through 7 days after the last study drug administration
- Incidence of abnormal blood work tests results, abnormal Urinalysis and positive Pregnancy testTime frame: At baseline, 72 to 96 hours after the last study drug administration, and on Day 7 after the first and the last study drug administration
- Change in vital signsTime frame: At pre-dose, over 96 hours after study drug administration, and on Day 7 after the last study drug administration
- Incidence of abnormal ECG parametersTime frame: At pre-dose, over 96 hours after study drug administration, and on Day 7 after the last study drug administration
- Incidence of abnormal physical examination findingsTime frame: At baseline, 96 hours after the last study drug administration, and on Day 7 after the last study drug administration
- Maximum observed plasma drug concentration (Cmax)Time frame: 0-96 hours
- Apparent terminal elimination half-life (t1/2)Time frame: 0-96 hours
- Time to maximum observed plasma drug concentration (Tmax)Time frame: 0-96 hours
- Area under the plasma drug concentration-time curve (AUC)Time frame: 0-96 hours
- Percentage of AUC0-∞ extrapolated from Tlast to infinity (AUCext)Time frame: 0-96 hours
- Apparent plasma clearance (CL/F)Time frame: 0-96 hours
- Apparent Volume of distribution (Vz/F)Time frame: 0-96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRG S&T Investigational Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.